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Chromosome microarray (CMA) analysis has rapidly re-
placed karyotype as a first-line cytogenetic test in children
with developmental delay, autism, or multiple congenital
anomalies. In the prenatal setting, karyotype is still the
go-to genetic test. Two recent back-to-back studies in The
New England Journal of Medicine provide a much-needed
comparison of karyotype and CMA in the prenatal setting,
thereby providing data for making cytogenetic-testing
decisions. Reddy et al. did the comparison on tissue
derived from stillbirths. One of the key advantages of
CMA in this setting is that, unlike in karyotype, tissue
culture is rarely necessary for microarray, and this increases
the likelihood of test success on this degrading tissue. In
this setting, CMA also identifies more genetic abnormali-
ties than does karyotype. The same holds true in the
Wapner et al. study in which amniocentesis and chorionic
villus samples were analyzed. For prenatal diagnosis, CMA
did just as well as karyotype at detecting aneuploidies and
unbalanced rearrangements. As expected, it also uncov-
ered copy-number changes that were not cytogenetically
visible, particularly when structural anomalies were de-
tected in the fetus. Although these data might suggest
that CMA is the way to go in the prenatal arena, one
must also take into account the increased cost and the
increased likelihood that a variant of uncertain signifi-
cance will be uncovered by CMA. Both of these factors
will most likely become less of an issue as CMA is used
more widely. The speed at which these changes occur is
highlighted by Wapner et al., who initially reported that
3.4% of their karyotypically normal patients had uncertain
findings by CMA. A prepublication reanalysis of these vari-
ants was performed on the basis of current literature, and
these uncertain results were cut by more than half to
1.5% of karyotypically normal patients.
Wapner et al. (2012). N. Engl. J. Med. 367, 2175–2184.
Reddy et al. (2012). N. Engl. J. Med. 367, 2185–2193.
MECP2 Overexpression Tied to Immune
Dysregulation
Either too much or too little MECP2 expression causes
severe syndromic neurodevelopmental defects. With the
loss of MECP2 function, there is Rett syndrome, whereas
duplications involvingMECP2 also cause a severe neurode-
velopmental disorder. TheMECP2 duplication syndrome is
well established, but one overlooked aspect of this pheno-1Department of Human Genetics, Emory University School of Medicine, Atlan
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Thetype is the susceptibility of affected individuals to recur-
rent infections. Some have hypothesized that this is due
to the fact that the smallest region of overlap in patients
with this syndrome includes not only MECP2 but also
IRAK1, which is involved in the toll-like-receptor (TLR)
pathway of the immune response. However, individuals
with this syndrome don’t have consistent deficits in this
pathway. Yang et al. recently found that MECP2 itself has
a role in the immune response. Transgenic mice that over-
express human MECP2 are less able to control certain
infections, and this is associated with a deficit in IFN-g
production. T cells from patients withMECP2 duplications
also produce less IFN-g, and this can be partially restored
with the use of short interfering RNA toMECP2. Although
the mechanism is not fully understood, MECP2 seems to
shift the histone modifications of chromatin in the region
and to thereby reduce IFN-g transcription.
Yang et al. (2012). Sci. Transl. Med. 4, 163ra158.
It Takes Two (or More)
The human body is obviously a complex biological system,
and this means that precise regulation of thousands of
genes is needed for keeping everything running smoothly.
In medical genetics, we often reduce our focus to single
genes at a time as a result of recognizable patterns of
Mendelian inheritance. This reductionist point of view
can limit our understanding of genetic disease. One
example is fascioscapulohumeral muscular dystrophy
(FSHD). The most common form requires that two genetic
variants occur in combination with each other. One
requirement is the contraction of an array of repetitive
elements called D4Z4 on chromosome 4; this contraction
alters the local chromatin conformation and yields expres-
sion of DUX4, a gene that is normally repressed in somatic
tissues. By itself, this contraction does not cause FSHD; in
order to get disease, the DUX4 transcript must be stable
inmuscle cells, and this property is conferred by a polyade-
nylation signal that is present on a particular D4Z4 haplo-
type. Some individuals with FSHD have the permissive
haplotype and chromatin relaxation in this region but do
not have contractions of D4Z4. Exome sequencing by
Lemmers et al. revealed that these individuals have
sequence variation at a completely independent locus,
SMCHD1. Reduced levels of the encoded protein, which
is involved in chromatin repression, relax the chromatin
around DUX4 and lead to ectopic expression of the gene,ta, GA 30322, USA
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as in the more common form of the disease. Interestingly,
almost 20% of individuals with a mutation in SMCHD1
and a permissive D4Z4 haplotype are asymptomatic.
Perhaps additional loci also contribute to the development
of this disease.
Lemmers et al. (2012). Nat. Genet. 44, 1370–1374.
Overview of Genetic-Testing Registry
When is one sequence better than another? It can be hard
to tell. Because each genetic diagnostic lab develops
a unique roster of test offerings and because the majority
of these tests are developed and validated in house,
comparing tests for identifying the most appropriate
testing laboratory for a certain situation can be daunting.
GeneTests is a remarkable resource for the identification
of testing labs that perform a certain test, but it is not
a repository of information on the individual tests them-
selves. Enter the Genetic Testing Registry, a project that
was developed by the National Institutes of Health in
response to a recommendation by the Secretary’s Advisory
Committee on Genetics, Health, and Society. As described
in a recent overview by Rubinstein et al., the Genetic
Testing Registry will be a resource for extensive informa-
tion on individual genetic tests; such information includes
details on the methodology, purpose, and clinical and
analytical validity and utility of the tests. Aided by curators
trained in medical genetics, individual-testing labs will
voluntarily submit data to the Genetic Test Registry for4 The American Journal of Human Genetics 92, 3–4, January 10, 2013each genetic test they perform, and this information will
facilitate comparisons of tests offered by different labs.
The Registry will eventually replace GeneTests, which is
expected to be phased out in 2013, although this will not
affect GeneReviews. As the Registry grows, it will enable
informed decision making on genetic testing.
Rubinstein et al. (2012). Nucleic Acids Res. 41, D925–D935.
Parental Interest in Risk Testing for Autism
Even if a genetic test does not give definitive results, the
majority of parents of children with autism would pursue
the test for their younger children who have not been diag-
nosed. This is according to an internet-based survey of
parents with at least one affected child. Many of the
parents perceived that there was a delay in the diagnosis
of their affected child as a result of a ‘‘wait and see’’
approach by their pediatricians, and this time period
before the diagnosis left them highly anxious. Testing
the younger child earlier was anticipated to reduce anxiety
by facilitating closer monitoring and earlier intervention.
Compared to more typical psychology-based testing, the
clinical utility of such a test was not assessed in this report.
Even if this testing is not as definitive, this survey suggests
that at least some parents would pursue risk-assessment
testing for autism.
Narcisa et al. (2012). Clin. Pediatr. (Phila). Published
online November 27, 2012. http://dx.doi.org/10.1177/
0009922812466583.This Month in our Sister JournalsIdentification of Loci for Variability in Gene
Expression
Although many genome-wide association studies (GWASs)
target loci involved in qualitative traits, GWASs can also be
adapted to detect quantitative trait loci. Often, these are
designed with a measurable clinical phenotype in mind,
but one can also look at gene expression as a quantitative
trait. Typically, the mean expression level is the ‘‘pheno-
type’’ used in this type of study; however, it is clear that
the expression of some genes is more tightly controlled
than others. What has been missing is an attempt to
uncover loci that govern the variability in gene expres-sion. Hulse and Cai adapted a model to find these loci,
and they applied this to publicly available genotype and
expression data from 210 individuals in the HapMap
project. They assessed loci with cis and trans effects and
sought loci that act singly or in combination with each
other. They found >200 genes for which the variability
in expression was significantly associated with at least
one marker in cis. Functional studies will help to clarify
the mechanisms by which these loci influence gene
expression.
Hulse and Cai. (2012). Genetics. Published online November
12, 2012. http://dx.doi.org/10.1534/genetics.112.146779.
